Bios Partners

ONL Therapeutics is a biopharmaceutical company headquartered in Ann Arbor, Michigan, that develops small‑molecule peptide therapeutics to protect photoreceptors and preserve vision. Its pipeline focuses on targeting the FAS apoptotic pathway to prevent photoreceptor loss in retinal diseases such as retinal detachment, aiming to improve surgical outcomes and reduce vision loss. Founded in 2006, the company seeks to bring novel treatments for serious, vision‑threatening retinal conditions.

Aileron Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel stabilized cell-permeating alpha-helical peptides for oncology and other therapeutic areas. Its lead product candidate, ALRN-6924, is in Phase 2a trials for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase I trials for acute myeloid leukemia and myelodysplastic syndrome.

ONL Therapeutics is a biopharmaceutical company headquartered in Ann Arbor, Michigan, that develops small‑molecule peptide therapeutics to protect photoreceptors and preserve vision. Its pipeline focuses on targeting the FAS apoptotic pathway to prevent photoreceptor loss in retinal diseases such as retinal detachment, aiming to improve surgical outcomes and reduce vision loss. Founded in 2006, the company seeks to bring novel treatments for serious, vision‑threatening retinal conditions.

Ocuphire Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for various ophthalmic disorders. Its lead product candidate, Nyxol eye drops, is a once-daily preservative-free formulation of phentolamine mesylate aimed at reducing pupil size for indications such as night vision disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia.

ONL Therapeutics is a biopharmaceutical company headquartered in Ann Arbor, Michigan, that develops small‑molecule peptide therapeutics to protect photoreceptors and preserve vision. Its pipeline focuses on targeting the FAS apoptotic pathway to prevent photoreceptor loss in retinal diseases such as retinal detachment, aiming to improve surgical outcomes and reduce vision loss. Founded in 2006, the company seeks to bring novel treatments for serious, vision‑threatening retinal conditions.

Azitra is a clinical-stage dermatology company that leverages skin microbiome knowledge to develop novel treatments for adverse skin conditions and diseases.

Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that inhibit glycogen synthase kinase-3 beta (GSK-3β) to treat cancer and neurodegenerative diseases. The company is advancing elraglusib (formerly 9-ING-41), a small-molecule GSK-3β inhibitor designed to disrupt signaling pathways that support tumor cell survival, growth, migration and invasion, with activity reported in challenging cancers such as glioblastoma, pancreatic, ovarian, and breast cancers. Actuate Therapeutics pursues combination approaches and aims to bring new agents to clinical development. Established in 2015, the company is based in Fort Worth, Texas, with an additional office in Dublin, Ireland.

Azitra is a clinical-stage dermatology company that leverages skin microbiome knowledge to develop novel treatments for adverse skin conditions and diseases.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative therapies for endothelial cell-mediated diseases, particularly those affecting the cornea. Utilizing its proprietary engineered fibroblast growth factor-1 technology platform, Trefoil aims to create first-in-class regenerative pharmacologic treatments for conditions such as Fuchs dystrophy and other serious corneal diseases that can lead to preventable blindness. The company is currently focused on a topical eye drop formulation known as TTHX1114, designed to treat ulcerative conditions on the cornea's surface, which can result in corneal scarring and significant vision loss. With a management team boasting over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil strives to enhance human health through protein-engineered drug therapies. As an early-stage company, it has received recognition from the biopharmaceutical funding community for its innovative business approach.

Lung Therapeutics, Inc. is a pharmaceutical company focused on developing innovative treatments for niche orphan drug indications related to lung injury and disease, particularly fibrosis. Based in Austin, Texas and incorporated in 2012, the company is dedicated to addressing severe complications associated with pneumonia, such as loculated pleural effusion, where fluid accumulation and scar tissue hinder drainage. Its lead product, LTI-01, is an injectable fibrinolytic drug designed to safely clear fibrinous scar tissue, facilitating the drainage of pleural fluid without the need for surgery. In addition to LTI-01, Lung Therapeutics is developing LTI-02 for acute lung injury and LTI-03 for idiopathic pulmonary fibrosis, aiming to enhance treatment pathways for these serious conditions. Through its targeted approach, Lung Therapeutics seeks to improve clinical outcomes for patients with life-threatening lung diseases.

Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that inhibit glycogen synthase kinase-3 beta (GSK-3β) to treat cancer and neurodegenerative diseases. The company is advancing elraglusib (formerly 9-ING-41), a small-molecule GSK-3β inhibitor designed to disrupt signaling pathways that support tumor cell survival, growth, migration and invasion, with activity reported in challenging cancers such as glioblastoma, pancreatic, ovarian, and breast cancers. Actuate Therapeutics pursues combination approaches and aims to bring new agents to clinical development. Established in 2015, the company is based in Fort Worth, Texas, with an additional office in Dublin, Ireland.

IN8bio, Inc. is a clinical-stage biotechnology company based in New York, focused on developing innovative therapies for cancer treatment utilizing gamma-delta T cells. These immune cells possess the unique ability to distinguish between healthy and diseased tissues, making them promising candidates for cancer therapies. IN8bio employs its DeltEx platform, which incorporates allogeneic, autologous, and genetically modified approaches to create effective cell therapies aimed at targeting and eliminating tumor cells. The company is currently conducting two investigator-initiated Phase 1 clinical trials for its lead product candidates: INB-200, designed for newly diagnosed glioblastoma, and INB-100, aimed at treating patients with high-risk leukemia undergoing hematopoietic stem cell transplantation. In addition to these clinical efforts, IN8bio has a diverse portfolio of preclinical programs targeting various solid tumor types. Founded in 2016 and originally known as Incysus Therapeutics, IN8bio rebranded in August 2020 to reflect its focus on advancing gamma-delta T cell therapies.

Immusoft is a biotechnology company that develops autologous cell therapies using its Immune System Programming (ISP) technology. Founded in 2009 and headquartered in Seattle, Washington, the company reprograms patients' cells to produce gene-encoded medicines for treating various diseases.

Azitra is a clinical-stage dermatology company that leverages skin microbiome knowledge to develop novel treatments for adverse skin conditions and diseases.

Lung Therapeutics, Inc. is a pharmaceutical company focused on developing innovative treatments for niche orphan drug indications related to lung injury and disease, particularly fibrosis. Based in Austin, Texas and incorporated in 2012, the company is dedicated to addressing severe complications associated with pneumonia, such as loculated pleural effusion, where fluid accumulation and scar tissue hinder drainage. Its lead product, LTI-01, is an injectable fibrinolytic drug designed to safely clear fibrinous scar tissue, facilitating the drainage of pleural fluid without the need for surgery. In addition to LTI-01, Lung Therapeutics is developing LTI-02 for acute lung injury and LTI-03 for idiopathic pulmonary fibrosis, aiming to enhance treatment pathways for these serious conditions. Through its targeted approach, Lung Therapeutics seeks to improve clinical outcomes for patients with life-threatening lung diseases.

Lantern Pharma Inc. is a clinical-stage biotechnology company based in Dallas, Texas, specializing in the development of precision oncology therapeutics through the integration of artificial intelligence, genomics, and machine learning. The company's lead drug candidate, LP-100, is currently undergoing phase II clinical trials for the treatment of metastatic, castration-resistant prostate cancer. Additionally, Lantern is advancing LP-300 as a combination therapy for female non-smokers with non-small cell lung cancer adenocarcinoma. Another promising candidate in preclinical development is LP-184, an alkylating agent targeting DNA in cancer cells that overexpress specific biomarkers. Lantern Pharma employs its proprietary RADR platform to enhance drug discovery and development, addressing challenges in patient stratification and understanding mechanisms of action, ultimately aiming to accelerate the delivery of personalized cancer therapies. The company was incorporated in 2013 and has positioned itself at the forefront of innovation in oncology.

Azitra is a clinical-stage dermatology company that leverages skin microbiome knowledge to develop novel treatments for adverse skin conditions and diseases.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.